Project

Inhibition of TNFR1 for the treatment of TNF mediated diseases

Code
3E017213
Duration
01 October 2013 → 25 March 2018
Funding
Regional and community funding: Special Research Fund, Research Foundation - Flanders (FWO)
Research disciplines
  • Medical and health sciences
    • Immunology
    • Orthopaedics
    • Immunology
    • Orthopaedics
    • Immunology
    • Orthopaedics
  • Engineering and technology
    • Biomaterials engineering
    • Biological system engineering
    • Biomaterials engineering
    • Biomechanical engineering
    • Other (bio)medical engineering
    • Environmental engineering and biotechnology
    • Industrial biotechnology
    • Other biotechnology, bio-engineering and biosystem engineering
Keywords
Anti-TNF therapy arthritis nanobodies Autoimmune disease TNF receptors Multiple Sclerosis Psoriasis
 
Project description

Anti-TNF therap is succesfully used for the treatment of autoimmune diseases like arthritis, IBD and psoriasis. Some of the complications associated with anti-TNF therapy such as increased risk for infections and new onset autoimmune diseases may be prevented by specific TNFR1 inhibition. This allows functional TNFR2 signaling which may be beneficial for the correct functioning of the immune system.